MedTrace Logo

A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy

NCT01245660 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2013-01-11

No results posted yet for this study

Summary

Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.

Conditions

  • Bladder Carcinoma
  • Infiltrative Bladder Carcinoma
  • Cystectomy

Interventions

DRUG

LAPATINIB

Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Geneviève CHENE, Pr · USMR Bordeaux

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01245660 on ClinicalTrials.gov